A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
暂无分享,去创建一个
S. Engel | K. Kaufman | I. Gantz | S. Suryawanshi | E. Lai | Sukrut Shah | E. O’neill | Menghui Chen | Catherine Ntabadde